You are on Trendlyne United States. Click here to go to India website or make United States as your default
person reading

About Delcath Systems Inc - Company Information, Overview, History and Profile

What does Delcath Systems Inc do?

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Delcath Systems Inc Management structure

All Gross Remunerations are in USD
Mr. Gerard J. Michel
Director and Chief Executive Officer
2.16 M
2024
Gross Remuneration
Year
Dr. Vojislav Vukovic, M.D.,PhD
Chief Medical Officer
1.09 M
2024
Gross Remuneration
Year
Dr. Martha S. Rook, PhD
Chief Operating Officer
933.1 K
2024
Gross Remuneration
Year
Mr. John Purpura, M.S.
Chief Operating Officer
-
2024
Gross Remuneration
Year
Ms. Sandra Pennell
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Johnny John, M.D.
Senior Vice President, Clinical Development and Medical Affairs
-
2024
Gross Remuneration
Year

Delcath Systems Inc Board of directors

All Gross Remunerations are in USD
Mr. John Richard Sylvester
Chairman of the Board
229.17 K
2024
Gross Remuneration
Year
Ms. Elizabeth A. Czerepak
Independent Director
205.67 K
2024
Gross Remuneration
Year
Mr. Steven Salamon
Independent Director
204.13 K
2024
Gross Remuneration
Year
Dr. Gilad Aharon, PhD
Independent Director
192.2 K
2024
Gross Remuneration
Year
Dr. Bridget Martell, M.A.,M.D.
Independent Director
176.25 K
2024
Gross Remuneration
Year
Dr. Roger G. Stoll,PhD
Independent Director
23.96 K
2024
Gross Remuneration
Year